On November 3, 2026, Matinas BioPharma Holdings, Inc. (the "Company") and a former financial advisor to the Company (the "Advisor") terminated the agreement between the Company and the Advisor. That agreement provided for, among other things, the payment to the Advisor of up to $2.0 million in cash and up to $2.0 million in stock in connection with the closing of certain business combinations. In connection with the termination, the Company paid the Advisor $562,500 in cash, and the Company and the Advisor exchanged mutual releases, subject to certain contingencies.

 

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.